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Monoclonal antibodies are currently used in the diagnosis ofgynecologic malignancies by way
ofimmunohistochemical assays, serum assays, and in situ radiolocalization ofcarcinoma lesions.
Among them is MAb B72.3, generated against a human tumor-associated antigen (TAG-72).
Using immunohistochemical techniques, MAb B72.3 has shown reactivity with 100 percent of
common epithelial ovarian carcinomas and endometrial carcinomas and non-reactivity with
normal adult tissues, with the exception ofnormal secretory endometrium. B72.3 appears to be a
valuable immunocytologic adjunct, with greater than 90 percent of effusions and fine-needle
aspiration biopsies from gynecologic carcinomas showing reactivity. Using a serum assay
developed to detect the presence of the TAG-72 antigen, 48 percent of patients with ovarian
carcinoma demonstrated TAG-72-positive sera versus 1 percent ofcontrol sera. "'I-labeled MAb
B72.3 IgG and gamma scanning have been used for the in situ detection ofmetastatic carcinoma.
Twelve of 15 patients with ovarian carcinoma showed positive gamma scans, and approximately
80 percent ofthe lesionsdemonstrated specific localization oftheantibody. These studies indicate
the potential utility ofMAb B72.3 in the diagnosis ofgynecologic carcinoma.
INTRODUCTION
Endometrial and ovarian carcinoma together are responsible for 19 percent of all
malignancies in women, with 39,000 and 18,000 new cases diagnosed each year,
respectively. Ovarian carcinoma is the fourth most frequent cause of cancer death in
women, and the leading cause of gynecologic cancer death in the U.S. [1], despite
recent advances in therapy [2]. Prognosis is critically dependent on the clinical and
surgical stages of the disease. Initial detection is often delayed because of the
asymptomatic nature of the disease; tumors have metastasized either regionally or
intraperitoneally in two-thirds ofall cases at the time ofinitial diagnosis [2].
The use of immunoglobulins in the diagnosis of gynecologic carcinoma may be
divided into three main areas: (a) immunohistochemical and immunocytochemical
assays, (b) serum assays, and (c) the useofradiolabeled monoclonal antibody (MAb) to
detect carcinoma lesions in situ. Several MAbs reactive with various tumor-associated
antigens (TAA) have demonstrated reactivity with gynecologic cancers, including
ovarian, endometrial, and cervical neoplasms [3-8]. Some of the more extensively
characterized monoclonal antibodies that show reactivity to ovarian carcinoma are
shown in Table 1. Some of these antibodies react preferentially with tumors of
non-mucinous epithelial origin and others react preferentially with mucinous ovarian
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TABLE 1
Monoclonal Antibodies Reactive with Human Ovarian Carcinoma
Reactive Antigen
Monoclonal Antibody (molecular weight) Reference
OC125 >200 K [6,8,23]
CA19-9 GICAa [11]
ID3,ID5 Unk [9]
OC133 80K [8]
B72.3 >106K TAG-72 [3,19]
HMFG1 HMW gp [15]
HMFG2 80-400 K
OVB3 Unk [10]
HB21 Human TFRab [18]
454A12 Human TFR [17]
454CIl Unk [16]
260F9
280Dl 1
245E7
MOvi Unk [12]
MOv2
MOv16 48-50 K [14]
MOvl8 38-40K
MOvl9 38-40 K
aGlycoprotidic antigen
bTransferrin receptor
Unk: Unknown
carcinomas. Of the former, OC125 reacts with virtually all ovarian carcinoma cell
lines tested, more than 80 percent ofnon-mucinous epithelial ovarian carcinomas, and
one of 12 non-ovarian neoplastic cell lines [6]. OC125 appears to demonstrate cell
surface binding to an antigen that exhibits better than 90 percent correlation with
disease regression or progression.
MAb OC133 detects a separate antigen and binds predominately to serous ovarian
neoplasms [9]. It is reactive with endometrium and endocervix but not with normal
ovary or fallopian tube. Antibodies ID3 and ID5 are representative of the group of
antibodies reacting with mucinous ovarian carcinoma; these two antibodies bind to
extracts of undifferentiated mucinous ovarian carcinoma but not to those extracts
tested ofnormal ovary, human serum, benign mucinous tumors, non-epithelial ovarian
carcinomas, or other malignant neoplasms [10]. MAb OVB3 raised against OVCAR-
3 cells shows reactivity with both mucinous and serous cystadenocarcinoma (but not
normal ovary) and reacts with 4/4 human ovarian cancer cell lines [11]. MAb
anti-carbohydrate 19-9 (anti-CA 19-9) also reacts with both mucinous and serous
ovarian carcinomas [12]. Two MAbs (MOvI and MOv2) were generated, using a
membrane preparation ofa mucinous ovarian cystadenocarcinoma [13]. MOv2 reacts
with the vast majority of mucinous, serous, and endometrioid carcinomas, as well as
benign serous and mucinous cystadenomas and some normal epithelia [14]. Using a
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TABLE 2
MAb B72.3 Reactivity with Formalin-Fixed Specimens of Human Neoplasiaa
No. Reactive/ >20% Reactive
Organ Histologic Tumor Type No. Tested (%) Malignant Cells (%)b
Ovary Serous cystadenocarcinoma 32/32 (100) 16/32 (50)
Mucinous cystadenocarcinoma 14/14 (100) 10/14 (71)
Uterus Endometrial carcinoma 32/32 (100) 26/32 (81)
Lung Squamous cell carcinoma 3/3 (100) 1/3
Adenocarcinoma 28/29 (97) 20/29 (69)
Large cell carcinoma 1/1 0/1
Colon Adenocarcinoma 51/54 (94) 23/54 (43)
Breast Invasive ductal carcinoma 37/44 (84) 12/44 (27)
aAdapted from [22]
bNumbers in parentheses show percentage.
poorly differentiated ovarian carcinoma as immunogen, MAbs MOv16, MOv18, and
MOvi9 were generated [15]; the latter two show restricted specificity for ovarian
carcinomas and cystadenomas.
Several MAbs originally directed against human breast cancer have shown cross-
reactivity with human ovarian neoplasms. For example, HMFG1 and HMFG2,
directed against a component of human milk fat globule membranes, react strongly
with adenocarcinoma oftheovary [16]. Four MAbsoriginallyobtained against human
breast cancer cells, 260F9, 454C11, 280D11, and 245E7, also cross-react with ovarian
carcinoma cell lines[17]. MAb 454A12 [18] and MAb HB21 [19], directed against
human transferrin receptor, have been conjugated to toxins and show anti-ovarian
tumor activity in vitro [19], using OVCAR cell lines and in a nude mouse model
[18].
Monoclonal antibody B72.3 [20] was developed by the immunization of mice with
membrane-enriched fraction of a metastatic breast carcinoma. It has demonstrated
reactivity with a mucin-like molecule of high molecular weight [21], termed tumor-
associated glycoprotein (TAG-72). MAb B72.3 has been reacted with a variety of
human adult and fetal tissues, using avidin-biotin-complex (ABC) immunohistochemi-
cal techniques to evaluate the expression of the reactive TAG-72 antigen [22]. Using
formalin-fixed, paraffin-embedded tissues or frozen sections, MAb B72.3 has demon-
strated reactivity with several types ofcarcinoma (Table 2), including most common
epithelial ovarian carcinomas, endometrial carcinomas, colorectal adenocarcinomas,
carcinomas ofthe breast, and non-small cell lung carcinomas, aswell as themajorityof
pancreatic and gastric carcinomas [22,23]. CA-125, an antigen first identified in an
ovarian carcinoma cell line [6], can be detected using MAb OC125 with frozen
sections in the majority ofnon-mucinous ovarian carcinomas [24]. Using frozen tissue
sections and modified ABC-immunoperoxidase techniques, Thor et al. demonstrated
that MAb B72.3 and MAb OC125 recognize distinct antigenic determinants and are
non-coordinately expressed [3]. MAb B72.3 is minimally or non-reactive with benign
lesions ofthe colon, breast, and ovary or with a varietyofnormal adult tissues [22]. An
exception is the reaction of MAb B72.3 with normal secretory endometrium (detailed
below, [23]). The pancarcinoma distribution of TAG-72 and lack of significant
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TABLE 3
MAb B72.3 Reactivity with Malignant Ovarian Tumorsa
No. Reactive/ >25% Reactive
Histologic Tumor Type No. Tested (%) Malignant Cells (%)b
Serous cystadenocarcinoma
Primary tumors 32/32 (100) 16/32 (50)
Metastatic tumors 16/30 (53) 13/30 (43)
Mucinous cystadenocarcinoma
Primary tumors 14/14 (100) 10/14 (71)
Metastatic tumors 7/7 (100) 6/7 (86)
Undifferentiated carcinomas
Primary tumors 8/8 (100) 3/8 (38)
Metastatic tumors 5/6 (83) 2/6 (33)
Endometrioid carcinoma
Primary tumor 1/1 0/1
Metastatic tumor 1/1 1/1
Clear cell carcinoma, primary 1/1 0/1
Malignant Brenner tumor, primary 1/1 0/1
aAdapted from [3]
bNumbers in parentheses show percentage.
reactivity ofMAb B72.3 with normal adult tissues suggest its potential diagnostic and
therapeutic use in the management ofgynecologic carcinomas.
REACTIVITY OF MAb B72.3 WITH OVARIAN NEOPLASMS
Theimmunoreactivity ofMAb B72.3 with epithelial ovarian neoplasms (accounting
for 80-90 percent of all ovarian neoplasms) has been well characterized [3]. Various
histologic types ofmalignant ovarian tumors were reacted with purified immunoglobu-
lin preparations of MAb B72.3, using the ABC immunohistochemical technique [25].
All 57 primary and 41 of 44 metastatic common epithelial tumors contained tumor
cells that were immunoreactive with MAb B72.3. The percentages of cellular
reactivity for epithelial tumors ranged from 1 to 100 percent for primary tumors and
from 0 to 95 percent for metastatic lesions (Table 3). Of the epithelial tumors
examined, 80 percent ofprimary and 75 percent of metastatic tumors demonstrated 5
percent or more reactive cells, whereas strong reactivity (.25 percent of malignant
cellsreactive) was present in approximately halfofprimary and metastatic carcinomas
(Table 3). Mucinous cystadenocarcinomas demonstrated the most cellular expression
ofTAG-72, with 71 percent ofprimary and 86 percent of metastatic tumors showing
strong cellular reactivity. Serous cystadenocarcinomas were less reactive, with 50
percent ofprimary and 43 percent ofmetastatic tumors demonstrating strong cellular
reactivity. Less frequent common epithelial tumor types, including undifferentiated,
endometrioid, and clear cell carcinomas were the least reactive, although 100 percent
of primary and 86 percent (six of seven) of metastatic tumors demonstrated cellular
expression ofTAG-72.
Some heterogeneity of TAG-72 expression was noted between primary and meta-
static masses, among various metastases, and within single tumor masses. There was
no strict correlation between the percentage ofcellular reactivity with MAb B72.3 and
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TABLE 4
Monoclonal Antibody B72.3 Reactivity with Endometrial Adenocarcinoma'
No. Reactive/ >75% Reactive
Clinicopathologic Parameterb No. Tested Malignant Cells
Endometrial carcinoma 32/32 19/32
(n= 32)
Depth ofinvasion
endometrium 3/3 2/3
1/3 myometrium 8/8 6/8
>1/2 myometrium 4/4 3/4
to serosa 2/2 1/2
Histologic tumor grade
I 8/8 3/8
I-II 4/4 2/4
II 9/9 7/9
II-IlI 2/2 2/2
III 4/4 1/4
Patient Age
<50 4/4 0/4
51-59 7/7 4/7
60-69 7/7 4/7
70-79 7/7 5/7
>80 2/2 2/2
aAdapted from [23]
bWhere available
the degree ofhistologic differentiation for either serous or mucinous cystadenocarcino-
mas. There was a trend, however, for those tumors that were least differentiated
(assigned to the undifferentiated tumor category) to show the lowest cellular reactivity
with MAb B72.3 in both primary and metastatic sites [3]. Synchronous metastases
from 19 of 20 cases showed similar levels of TAG-72 as in the primary epithelial
neoplasm [26].
REACTIVITY OF MAb B72.3 vs. ENDOMETRIAL NEOPLASMS
The expression ofTAG-72 in endometrial carcinomas [23] was studied using MAb
B72.3 and a modification of ABC immunoperoxidase methods [25]. Thirty-two of 32
cases of endometrial adenocarcinoma were reactive, although heterogeneity in the
expression ofTAG-72 by malignant epithelial cells was observed. These cases could be
separated into two groups, based on percentage of cellular reactivity: nineteen cases
showed >75 percent cellular reactivity, and 13 cases showed reactivities between 1 and
50 percent. There was no striking correlation between percentage ofcellular reactivity
with MAb B72.3 and depth of tumor invasion, histologic tumor grade, or patient age
(Table 4).
Secretory endometrium has also been shown to react with MAb B72.3, whereas
proliferative phase specimens were negative [22]. This observation prompted a more
detailed study of normal endometrial reactivity to help define which physiologic
conditions might regulate TAG-72 expression [23]. As shown in Table 5, all 38
post-ovulatory (secretory) specimens showed cellular reactivity with MAb B72.3 with
an average percentage of reactivity of 40.8 ± 28.6 percent. The average percentage
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TABLE 5
MAb B72.3 Reactivity with Normal Endometriuma
No. Reactive/ >25% Reactive
Endometrial Phase No. Tested Cells
Proliferative endometrium (n = 7)
(day 7-13) 0/7 0/7
Secretory endometrium (n = 38)
(day 16-20) 6/6 3/6
(day 21-24) 22/22 13/22
(day 25-28) 10/10 8/10
Resting endometria from
post-menopausal patients (n = 10) 0/10 0/10
'Adapted from [23]
ofcellular reactivity was not statistically different in the early, middle, or late
post-ovulatory samples. Middle to late proliferative phase endometria (n = 7) failed
to demonstrate reactivity with MAb B72.3. Ten resting endometria from post-
menopausal women failed to react with MAb B72.3.
THE USE OF MAb B72.3 AS AN ADJUNCT IN THE
IMMUNOCYTOLOGIC DIAGNOSIS OF GYNECOLOGIC CARCINOMA
The vast majority of immunocytochemical studies in clinical cytology have been
applied to specimens of serous effusions and fine-needle aspiration biopsies (FNAB).
These types ofspecimens are likely tocontain cancer cells in a significant proportion of
cases [27-29]. When compared to other types of cytologic specimens, effusions and
FNABs are notorious for the pitfalls that may be encountered in their interpretation.
Effusions may contain reactive but benign mesothelial cells, which may mimic cancer
cells. If malignant cells are present, recognition of their origin may be impossible by
conventional morphological analysis alone. FNABs may also present significant
limitations and diagnostic problems in spiteoftheir current effectiveness and accuracy
when interpreted in experienced laboratories. The type of specimen obtained from an
FNAB has features ofboth a tissue section from an open biopsy and purely exfoliated
cells. Thus the diagnostic problems posed by an undifferentiated malignant neoplasm
in a histologic section may become even more difficult in a fine-needle aspirate.
MAb B72.3 has demonstrated utility as an immunocytologic adjunct to diagnosis of
carcinoma in cell block and cytocentrifuge preparations of human serous effusions,
with selective reactivity for tumor cells (particularly adenocarcinoma) over reactive
mesothelium [30,31]. Using the ABC-immunoperoxidase method on formalin-fixed,
paraffin-embedded cell blocks, MAb B72.3 detected tumor cells in 97 percent of
effusions from patients with ovarian serous cystadenocarcinoma (Table 6). Ninety-
three percent ofcarcinomas ofthe uterus and cervix reacted with B72.3, including all
38 endometrial carcinomas (Table 6). In addition, MAb B72.3 detected tumor cells in
effusions from the majority of patients with adenocarcinoma, including those from
lung (non-small cell), breast, and gastrointestinal tract. In contrast, 821 benign
effusions showed no reactivity with MAb B72.3 (Table 6).
MAb B72.3 has also been used with FNABs and corresponding surgically excised
tumors to determine cellular reactivity [29,311]. Positive staining with MAb B72.3 was
observed in 91 percent (10of 11) ofFNABs fromovarian serouscystadenocarcinomas;
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TABLE 6
Summary of Immunoreactivity of Effusions and FNABs with MAb B72.3'
Reactivity ofEffusion: Reactivity of FNAB:
No. Reactive/ No. Reactive/
Lesion No. Tested (%) No. Tested (%)
Ovary
Adenocarcinoma 110/113 (97) 10/11 (91)
Uterus and cervix 40/43 (93) 32/35 (91)
Lung
Benign lesions 0/99 (0)
Non-small cell carcinoma 36/40 (90) 145/157 (92)
Breast
Benign lesionsb 0/10 (0)
Adenocarcinoma 43/46 (93) 40/44 (91)
Gastrointestinal tract 14/17 (82) 36/41 (88)
Miscellaneous benign aspirates 0/326
Benign effusions 0/821
'Adapted from [31]
bExcluding apocrine metaplasia
32 of35 (91 percent) carcinomas oftheuterus and cervix, including all 30 endometrial
adenocarcinomas, demonstrated reactivity with MAb B72.3. In addition, positive
staining with MAb B72.3 was observed in FNABs from the majority of carcinomas
from the lung (non-small cell), breast, and gastrointestinal tract, whereas most benign
lesions showed no staining (Table 6). In many cases, tumor-bearing tissue had also
been resected and was available for comparative examination with MAb B72.3. In
more than 90 percent ofthese cases, the staining pattern oftumor cells in the FNABs
was predictive of antibody reactivity in the comparable surgically resected tumors.
From these studies, we concluded that MAb B72.3 may be used as an adjunct for the
diagnosis ofneoplasms in effusions and FNABs.
THE USE OF AN MAb TO DISTINGUISH OVARIAN CARCINOMA
FROM COLORECTAL CARCINOMA
The distinction between primary ovarian carcinomas and metastatic carcinoma to
the ovary from another site may be difficult using clinical, surgical, and pathologic
criteria. Cancers which commonly metastasize to the ovary include carcinoma of the
breast, gastrointestinal tract, and genital tract [32]. MAb COL-4, reactive with
carcinoembryonic antigen, has been shown to react preferentially with adenocarcino-
mas of the colon versus a variety of normal tissues [33]. Using ABC-immunoperoxi-
dase techniques, Thor et al. [34] demonstrated differential reactivity of MAb COL-4
with colon carcinoma versus ovarian carcinoma (Table 7). COL-4 reacted with the
vast majority of primary (n = 50) and metastastic (n = 62) colonic carcinomas. In
contrast, MAb COL-4 demonstrated little or no reactivity with primary (n = 53) and
metastatic (n = 23) carcinomas of the ovary using >10 percent reactive cells as an
arbitrary criterion (Table 7). Hence MAb COL-4 can be used as an immunohisto-
chemical adjunct for the differentiation ofovarian fromgastrointestinal adenocarcino-
mas.
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TABLE 7
Reactivity of Human Colon and Ovarian Carcinoma with MAb COL-4'
No. Reactive/ >10% Reactive
Lesion No. Tested (%)b Malignant Cells (%)
Colon Carcinoma
Primary 49/50 (98) 35/50 (70)
Regional metastases 40/42 (95) 27/42 (64)
Distant metastases 19/20 (95) 11/20 (55)
Ovarian Carcinoma
Primary 9/53 (17) 1/53 (2)
Metastatic 6/23 (26) 1/23 (4)
aAdapted from [34]
bNumbers in parentheses show percentage.
DETECTION OF TAG-72 IN SERA OF CARCINOMA PATIENTS
Serum assays employing specific MAbs may be useful in detecting occult carci-
noma, monitoring the efficacy of standard therapy, and identifying potential patients
for therapy with a specific MAb. A rigorous effort is under way to identify TAAs that
can lead to the detection of early ovarian carcinoma, because most patients currently
are diagnosed when they already have advanced disease. Several serum assays for
ovarian TAA arecurrently in use, including CEA, CA125, CA15-3 [1,35], and human
placental alkaline phosphatase [36].
Serum assays for the detection ofCA125 have been shown to be a sensitive marker
for the presence of non-mucinous ovarian tumors [35]. Using a value of >65 U/ml,
Soper et al. [37] have shown a sensitivity of 90 percent; however, 7 of 47 (15 percent)
patients with benign pelvic masses had elevated (>65 U/ml) CA125 in their serum
(see below).
An immunoradiometric assay has been developed using MAb B72.3 to quantitate
TAG-72 in human serum [38]. In a simultaneous immunoradiometric assay, the mean
TAG-72 concentration in 1,099 serum samples from healthy blood donors was 1.83 +
2.03 U/ml. An upper limit ofnormal of 10 U/ml included 99 percent ofhealthy blood
donors. There was no significant (p < 0.06) effect of sex upon TAG-72 levels in the
blood donor group in which age and sex were known (n = 675). This is important in
light of the strong expression of TAG-72 by secretory endometrium. Nine of 19 (47
percent) patients with ovarian carcinoma demonstrated TAG-72 positive serum
samples; the average TAG-72 level in ovarian carcinoma patients was 65.42 U/ml.
Only four of 101 (4 percent) serum samples from patients with benign gastrointestinal
disease were elevated, whereas 15 of 26 (58 percent) and 14 of 25 (56 percent) sera
from patients with rectal and colon carcinoma, respectively, were positive. The ability
ofthis assay to discriminate between malignant and benign disease suggests its further
evaluation for monitoring patients with known or suspected carcinoma [38], either
alone or in combination with preexisting assays.
Soper et al. [37] used thecombination ofCA125 and TAG-72 serum levels to detect
non-mucinous ovarian tumors; 46 percent (18 of39) ofpatients with malignant disease
had positive levels (>10 U/ml) ofTAG-72 and only 2 percent ofpatients with benign
pelvic disease had positive serum levels of TAG-72. When TAG-72 was used in
combination with CAI25, the specificity was increased to 98 percent.
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A prospective study [39] using the combination ofTAG-72 and CA125 is currently
being conducted on 5,000 apparently healthy women to determine whether use of a
combination ofmarkers might permit cost-effective screening for occult malignancy in
an apparently healthy population.
USE OF RADIOLABELED MAb B72.3 FOR THE LOCALIZATION
OF METASTATIC CARCINOMA
Studies have demonstrated that radiolabled MAbs to TAAs can detect carcinoma
lesions using gamma scanning. These studies were conducted using MAbs to car-
cinoembryonic antigen. MAbs 1083-17-lA and 19-9, and MAbs to human milk fat
globule membranes [40-51].
The administration of 311-labeled B72.3 in patients with colorectal carcinoma and
the quantitative evaluation of its reactivity with tumor versus a wide range of normal
tissues has been recently reported [52]. Gamma scanning followed by a comprehensive
direct examination of tumor and a variety of normal tissues was achieved. Specimens
were weighed and placed in a gamma counter to determine counts per minute (cpm)
per gram values. Fixed biopsy specimens were analyzed for (a) percentage of tumor
cells present and (b) TAG-72 antigen-positive cells using MAb B72.3 and ABC-
immunoperoxidase techniques. Positive gamma scans (confirmed at surgery) were
observed in 14 of 27 patients and in 10 of 20 patients in whom direct examination of
tissues was available. This result is rather promising considering that "'I was used,
since this isotope is not optimal for gamma scanning. Gamma scans accurately
identified tumor lesions in the liver, bone, orbit, rectum, colon, cecum, pelvis, and
diffusely in the peritoneal cavity. No anaphylaxis, serum sickness, bone marrow
suppression, or other toxicity was observed [52].
The radiolocalization index (RI) value is defined as the ratio of the uptake of
131I-labeled MAb per gram of tumor to that of histologically confirmed normal tissue;
average values (cpm per gram) from biopsy of normal liver and/or normal intestinal
tissue ofeach patient were normalized to 1.0. RI values >3 were arbitrarily considered
as "positive" for these studies. At least one tumor lesion in 17 of 20 of the colorectal
cancer patients studied had an RI .3. In eight of these patients, all 50 tumor lesions
biopsied had RI 23. In total, 99 of 142 (70 percent) carcinoma lesions biopsied showed
RI values 23. Of 210 histologically confirmed normal tissues biopsied, 198 had
negative (<3) RI values [52].
Martin et al. have used a hand-held, gamma-detecting probe intraoperatively to
detect carcinoma lesions following an intravenous administration of '25I-labeled B72.3
[53]. Positive probe counts were detected in 47 of66 patients (71 percent) with various
carcinomas, including ovarian carcinoma.
Salvatore et al. [54] performed radioimmunoscintigraphy following intravenous
injection of either 3'I- or "'In-labeled B72.3 on a variety of patients with primary or
metastatic carcinoma. Twelve of 15 patients with ovarian carcinoma showed positive
gamma scans, with 27 of 33 carcinoma lesions detected (82 percent).
INTRAPERITONEAL ADMINISTRATION OF RADIOLABELED MAb
B72.3 AND TARGETING OF CARCINOMA IMPLANTS
Recent studies were conducted to (a) determine the feasibility of intraperitoneal
administration of radiolabeled B72.3 for peritoneal tumor localization, (b) compare
tumor localization ofintravenously versus intraperitoneally administered MAb by the
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PATIENT MM
IMMEDIATE 3 DAYS 6 DAYS
PATIENT RK
IMMEDIATE 3 DAYS 7 DAYS
FIG. 1. Radioimmunoscintigraphy in patients with metastatic colorectal cancer after intraperitoneal
administration of 131 1-72.3 IgG [55]. Two patients were scanned immediately after antibody administra-
tion and at various times. A positive scan is seen in patient MM, where '31 1-72.3 localizes peritoneal
implants. In patient RK, no peritoneal tumor is present and there is no MAb localization observed. Both
patients show accumulation of radiolabeled MAb in the peritoneal gutters immediately after intraperito-
neal MAb administration and in the bladder at three days after intraperitoneal administration.
stimultaneous administration of '251I-labeled B72.3 intravenously, and '311-labeled
B72.3 intraperitoneally, and (c) define the pharmacokinetics of plasma clearance of
both intraperitoneally and intravenously administered radiolabeled MAb B72.3.
All patients were part of a pre-existing NCI Surgery Branch protocol for the
surgical resection of suspected or confirmed peritoneal metastatic colorectal carci-
noma followed by intraperitoneal administration of therapeutic agents. Four to seven
days before surgery, all patients were administered 1311-labeled B72.3 intraperitoneally
via a catheter. All patients received between 0.76 and 1.2 mg of IgG and between 5.0
and 1i0.0 MCi '3'1, with specific activities of s31nn-B72.3 IgG ranging from 6.6 to 1.0
mCi/mg [55,56].
On the day of or prior to surgery, patients were scanned with a gamma camera; all
scan results were interpreted before surgery. Gamma scans of seven of ten patients
showed clearly discernable concentrations of radiolabeled MAb in various distinct
regions of the peritoneum. In all such cases, these lesions were identified at surgery as
tumor and later confirmed as carcinoma via light microscopic examination. A represen-
tative positive gamma scan is shown in Figs. 1IA-IC (patient MM). Note the
accumulation of radiolabeled MAb in the peritoneal gutters immediately after
intraperitoneal MAb administration (Fig. 1nA) and at three days after MAb adminis-
tration (Fig. 1B). The gamma scan at six days post-MAb administration, however,
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TABLE 8
RI Values of Patients Injected Intraperitoneally with '3'I-Labeled B72.3a
RI
Tumor Normal
Name <3 3-10 >10 <3 3-10 >10
NM 0 1 17 12 0 0
MH 2 4 0 10 0 0
RK 5 3 0 8 0 0
MM 4 5 18 11 0 0
MG 11 0 0 7 0 0
WJ 2 7 3 25 0 0
EP 0 7 2 1 0 0
SM 5 6 1 6 0 0
JB 0 0 6 12 1 0
JK 0 0 3 3 0 0
Total Lesions 29 33 50 95 1 0
Percentage 26 29 45 99 1 0
aAdapted from [56]
shows MAb concentration in distinct areas ofthe peritoneum (confirmed as carcinoma
at surgery and by light microscopic examination). These findings can be contrasted
with the negative gamma scans ofpatient RK (Figs. 1D-1F); who had no intraperito-
neal disease [56].
Three of the ten patients studied were positive for MAb localization via gamma
scanning (confirmed at surgery) but were negative for tumor via CT scan and X-ray
studies. Lesions as small as approximately 1.5 cm in diameter were clearly defined by
gamma scans. All specimens removed at surgery were analyzed for cpm per g oftissue.
Specimens were then fixed, embedded, and analyzed for percentage ofcarcinoma cells
present.
Table 8 shows the RI values (based on % ID MAb uptake per kg oftumor versus %
ID MAb uptake per kg ofnormal tissue) ofthe biopsy specimens oftumor and normal
tissues from the ten patients receiving intraperitoneally administered MAb B72.3. An
RI of >3 was arbitrarily chosen as a positive radiolabeled uptake; 83 of 112 (74
percent) of carcinoma lesions showed RI values -3. In some patients with a large
tumor burden, as much as 40 percent of the injected dose was bound to carcinoma.
Note that of the 29 lesions negative for MAb uptake, 11 were from patient MG, the
only patient in whom all tumor lesions were negative for TAG-72 antigen expression.
Of the 95 histologically confirmed normal tissues biopsied, all but one demonstrated
RI values <3 (Table 8). The one exception had an RI of 3.5 and was a histologically
normal spleen from patient JB. Interestingly, this patient had the highest level of
circulating antigen '31I-B72.3 IgG immunecomplex asdetermined by HPLC and RIA.
The other 94 normal tissue biopsies with RI values <3 were from numerous sites,
including colon, ileum, duodenum, pancreas, liver, spleen, lymph node, kidney, ovary,
and fallopian tube; the vast majority of RI values ranged from 0.5 to 1.5 [56].
Studies were next conducted to determine the relative efficacies ofintraperitoneally
versus intravenously administered MAb to localize tumor lesions [56]. Patients were
concomitantly administered "3'I-labeled B72.3 intraperitoneally and '25I-labeled B72.3
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TABLE 9
Concomitant Administration of "1'I-B72.3 Intraperitoneally and '25I-B72.3 Intravenously (Patient NJ):
Advantage of Intraperitoneal Routea
% ID/kg RIb
%ID/kg
Intraperitoneal Intravenous Ratios Intraperitoneal Intravenous %
Tissue Description 131i 125i 13I/1251 131I 125i Tumor
Carcinoma
Omentum
Mesentery,
sigmoid colon
Peritoneum,
liver capsule (n =
4)
Peritoneum, gastro-
esophageal junc-
tion
Omentum, greater
Peripancreatic
Omentum, lesser
(n = 2)
Diaphragm (n = 3)
Splenic capsule (n =
4)
Normal
Adipose tissue
Mesentery,
transverse colon
Peritoneum
Peritoneal
adhesions (n = 3)
Abdominal scar
Falciform ligament
Spleen (n = 3)
44.51
40.04
39.62
39.27
11.41
45.27
27.08
27.23
29.30
0.07
0.52
0.84
1.21
0.99
1.04
2.70
5.85 7.61
5.42 7.39
9.19 5.64
8.45 4.65
2.75 4.16
11.30 4.01
7.54 3.68
7.76 3.48
10.72 2.77
0.05 1.31
0.49 1.07
0.66 1.26
0.78
0.47
0.37
3.45
1.56
2.09
2.82
0.78
32.6
29.3
29.0
28.8
8.4
33.2
19.8
19.9
21.5
0.1
0.4
0.6
0.9
0.7
0.8
2.0
12.2 80
11.3 80
19.1 66
17.6 80
5.7 40
23.5 85
15.7 63
16.2 68
22.3 69
0.1 0
1.0 0
1.4 0
1.6 0
1.0 0
0.8 0
7.2 0
'Adapted from [56]
bRI was determined by dividing the % ID/kg of the tumors by the averaged % ID/kg of all normal
biopsies.
intravenously. Both the intraperitoneally and intravenously administered MAb prepa-
rations in each of four patients were identical in milligram dose and radiolabeling
conditions. In 35 of 55 carcinoma lesions biopsied, the intraperitoneally administered
B72.3 localized at least two times better in terms of % ID/kg than the intravenously
administered MAb. In seven lesions, MAb localization was comparable via either
route, and in 13 lesions, the intravenously administered MAb B72.3 localized at least
two times better than the intraperitoneally administered MAb. For example, as noted
for patient NJ (Table 9), the % ID/kg taken up bycarcinoma lesions ranged from 11.4
to 45.3 for intraperitoneally administered B72.3 (1'3I cpm/kg) versus valuesofonly 2.8
to 11.3 percent ID/kg for the intravenously administered B72.3 ("25I cpm/kg). The
ratios ofuptake ofthe intraperitoneally administered MAb were from 2.8 to 7.6 times
greater for individual lesions than the intravenously administered MAb. The levels of
uptake in the normal tissues were similar [56].
In an attempt to determine the reason(s) for the difference in uptake ofintraperito-
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neally and intravenously administered MAb among different carcinoma lesions, three
pathologists independently examined these lesions (two did so without knowing the
reason for the exercise) and characterized them as to various properties. The most
striking correlation with differential MAb uptake was the type of metastasis, i.e.,
either peritoneal implant (in which intraperitoneal route was superior) or "non-
implant" (in which intravenous route was superior).
Plasma samples from eight different patient studies were obtained before MAb
administration and at various time points after MAb administration [56]. The plasma
clearance of the intravenously administered '25I-labeled B72.3 IgG and the 1251I-BL-3
control IgG were similar, with approximately 50 percent ofthe injected dose in plasma
atday 7 post-MAb administration. In contrast, no more than 30 percent ofthe injected
dose of intraperitoneally administered B72.3 IgG or BL-3 appeared in the plasma at
any point in time, with peak values obtained at days 2 to 3.
There are several diagnostic implications from these studies. Radiolabeled B72.3
may now be considered for use in the localization of suspected colorectal or ovarian
carcinoma lesions. Carcinoma can be detected by intraperitoneally administered
"3'I-labeled B72.3 when in some cases, other radiologic procedures, including CT scan,
may not detect lesions [56]. Ovarian carcinoma, because its metastases are often
limited as implants in the peritoneum, is an ideal type of tumor for immunodiagnosis
and immunotherapy using intraperitoneally administered MAb. Based on intraperito-
neal administration of radiolabeled B72.3 in colorectal patients and early reports in
ovarian carcinoma patients [53,54], B72.3 may be a useful diagnostic and therapeutic
modality for ovarian carcinoma patients, using MAb B72.3 either coupled to drugs,
effector cells, or radionuclides. Preliminary reports from several institutions have
shown localization of radiolabeled B72.3 to biopsy-proven ovarian carcinoma lesions,
including subdiaphragmatic and peritoneal implants. Direct analysis of biopsy and
plasma specimens have permitted dosimetry calculations [57] that indicate, in selected
patients, higher doses of '31I-B72.3 IgG may be delivered to tumor masses for cell
killing with minimal toxicity to normal tissues. Efficiency of killing will increase,
moreover, when more efficient cytotoxic radionuclides, such as 90Y, are coupled to
MAbs; studies to develop such reagents are currently in progress. It has been shown
that only a fraction of the intraperitoneally administered radiolabeled MAb IgG is
found in the plasma at any time, potentially an important point to consider if one
wishes to minimize plasma-borne radiolabeled MAb as a possible source of marrow
toxicity. Thus, these studies have demonstrated the necessity ofconsidering either sole
use of intracavitary administered MAb or the concomitant use of intracavitary and
intravenously administered MAb in protocols aimed at MAb-guided diagnosis or
perhaps therapy ofgynecologic carcinomas.
In summary, monoclonal antibodies may make significant contributions to the
management of gynecologic malignancies. Because of the asymptomatic nature of
ovarian carcinoma, early diagnosis is essential to prognosis. Through the use of serum
assays, MAbs may identify asymptomatic patients. Radioimaging with '3'I-labeled
MAb has detected carcinoma lesions that otherwise escaped the usual radiologic
detection methods. Due to the suboptimal imaging characteristics of '3'I, the use of
low-energy gamma emitters such as "'In, 99mTc, or 1231, which have favorable scanning
properties, will result in better diagnostic gamma scans. Immunohistochemical assays
and serum assays may be important in the selection of appropriate patients whose
tumors demonstrate high levels ofa given tumor antigen.
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